Health Economics and Outcomes Research need to be included in companies' product development strategy in order to ensure a focus on the specific market and to maximize reimbursement, funding, market access and product uptake at launch and beyond.
The IMS Health Economics and Outcomes Research team is uniquely positioned to support you optimising market access based on a strategy addressing the regulatory framework, all economic issues and considering the collection of all information necessary for future reimbursement and marketing applications. The IMS team draws on it's vast healthcare market intelligence and experienced professionals that are available to you with relevant and accurate advice for strategic decision making at all stages of product development - from pre-clinical to post-launch.
We work closely with you to develop your HEOR strategic plans that optimise your resources to address current and future needs. An important area to understand and consider is the structure and function of the legal frame work of the health care systems in the different countries or in your specific country. Identifying trends and new opportunities in the market place and designing clinical trials that integrate health economic outcomes with safety/efficacy outcomes are two other examples where strategic planning saves both time and money.
A compelling need
For companies planning a global launch, understanding the legal framework of
the different health care systems, allocating resources and establishing appropriate
data collection can be particular challenges.
The pharmaceutical marketplace is constantly changing influenced by such factors as new drug developments, changing patient and physician requirements and evolving healthcare systems. From the manufacturers perspective the ability to respond quickly to changes and, where possible, influence policy decisions affecting the industry is essential. Keeping informed is a critical part of this process but is often a challenge to achieve, especially on a global scale. Being located in numerous countries and having worked with decision makers in a broad range of countries the IMS HEOR team is very close to key authorities and decision makers and has proven the ability to influence outcomes.
Clinical trials, previously designed solely to demonstrate product efficacy and safety, are increasingly being designed to incorporate outcomes indicators that can be used to support health economic evaluations. This approach eliminate the need for additional trials focusing only on economic outcomes. However in these trials, the indicators need to be carefully selected to ensure collection of the most relevant information making information rendering the trial too cumbersome to complete. That is why deep knowledge of therefore familiarity with the requirements for health economic analyses is essential.
The IMS HEOR solution
-
Market assessment, forecasting and access
-
Strategy papers
-
Strategy implementation
-
Influence policy decisions
-
Clinical trial design